Research advances of immune checkpoint inhibitors in the treatment of metastatic castration-resistant prostate cancer
With the success of immunotherapy in other oncology areas, prostate cancer has also entered the era of immunotherapy. At present, the immune checkpoints (ICs) in the prostate cancer field have been studied deeply, including CTLA-4 and PD-1/PD-L1 pathways. This article reviews the recent progress of immune checkpoint inhibitors (ICIs) monotherapy or combination therapy in patients with advanced prostate cancer, and discusses its development direction and application prospect.
万方数据
